艾司西酞普兰合并奥氮平治疗难治性抑郁症疗效观察

A comparative study of escitalopram augmented with olanzapine in the treatment of refractory depression

目的探讨艾司西酞普兰合并奥氮平对难治性抑郁症的临床疗效。方法将55例难治性抑郁症患者随机分为研究组(艾司西酞普兰合并奥氮平)和对照组(单用艾司西酞普兰),疗程为12周,采用汉密尔顿抑郁量表(HAMD)评定临床疗效,副反应量表(TESS)评定不良反应。结果治疗结束后,两组HAMD评分较治疗前均有显著性降低(P<0.05)。治疗后第8、12周末,研究组的HAMD评分显著低于对照组,且差异有显著性意义(P<0.05)。两组副作用均较小,研究组仅在体重增加、嗜睡方面较对照组高,差异有显著性意义(P<0.05)。结论艾司西酞普兰合并奥氮平治疗难治性抑郁症能明显提高疗效,安全可靠。

Objective To investigate the efficacy of escitalopram combined with olanzapine in the treatment of refractory depression. Methods A total of 55 patients were randomly divided into study group treated with escitalopram combined with olanzapine and control group treated with olanzapine for 12 weeks. The efficacy and side effects were evaluated with Hamilton Depression Rating Scale （HAMD） and Treatment Emergent Symptom Scale （TESS）. Results Scores of HAMD in two groups both decreased significantly （P 〈 0.05 ） after the treatment. Scores of HAMD in study group were significantly lower than that in control group at the 8th and 12th weekend （P 〈 0.05 ）. Side effects in the two groups were mild, but the frequency of weigh gain and hypersomnia in study group were significantly higher than those in control study （ P 〈 0.05 ）. Conclusion Escitalopram augmented with olanzapine has better effect than escitalopram monotherapy in the treatment of refractory depression with satisfactory tolerability.